Phase III trial of AK111 for active ankylosing spondylitis completed with 510 patients
Can a new drug help people with painful spinal arthritis move more freely?
A Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluated AK111 in 510 patients with active ankylosing spondyli…
A new drug called AK111 aims to help people with painful spinal arthritis move more freely by improving symptoms like pain and stiffness.
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Canakinumab shows efficacy in Japanese AOSD patients in Phase 3 open-label study
Could a monthly injection help control the painful flares of Adult-Onset Still's Disease?
A Phase 3, open-label, single-arm study evaluated canakinumab in 14 Japanese patients with Adult-Onset Still's Disease.
A monthly injection helped Japanese patients with Adult-Onset Still's Disease achieve meaningful symptom relief, supporting approval for thi…
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.